Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.

An overview is given of serum and urine prostate cancer markers that are currently under investigation and subsequently the P-Mark project is introduced. There are many markers showing promise to overcome the limitations of prostate specific antigen (PSA). Eventually, these markers should be able to increase the specificity in diagnosis, differentiate between harmless and aggressive disease and identify progression towards androgen independence at an early stage. In the P-Mark project, several recently developed, promising markers will be evaluated using clinically well-defined biorepositories. Following successful evaluation, these markers will be validated on a sample set derived from two large, European, prostate cancer studies and used for the identification of special risk groups in the general population. In addition, novel markers will be identified in the same biorepositories by different mass spectrometry techniques.

[1]  J. Richie,et al.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.

[2]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[3]  K. Akakura,et al.  Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. , 2003, European urology.

[4]  M. Karas,et al.  Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. , 1988, Analytical chemistry.

[5]  A. Partin,et al.  Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. , 2003, Urology.

[6]  J. Witte,et al.  CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  W. Catalona,et al.  Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. , 2004, Clinical chemistry.

[8]  S. Loening,et al.  Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications , 2004, International journal of cancer.

[9]  A. Stieg,et al.  Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. , 2003, Urology.

[10]  V. E. Goldberg,et al.  Tartrate-Resistant Acid Phosphatase as a Marker of Bone Metastases in Patients with Breast Cancer and Prostate Cancer , 2004, Bulletin of Experimental Biology and Medicine.

[11]  A. Partin,et al.  Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6–4.0 ng/mL range of total PSA , 2004, BJU international.

[12]  K. Miller,et al.  DNA-based detection of prostate cancer in urine after prostatic massage. , 2001, Urology.

[13]  H. Kijima,et al.  Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers. , 2003, Medical Science Monitor.

[14]  A. Marshall,et al.  Fourier Transform Ion Cyclotron Resonance Spectroscopy , 1974 .

[15]  M. Kohli,et al.  Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. , 2003, Urology.

[16]  K. Groenier,et al.  Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis , 2001, BJU international.

[17]  M. Mann,et al.  Electrospray ionization for mass spectrometry of large biomolecules. , 1989, Science.

[18]  M. Roobol,et al.  The story of the European Randomized Study of Screening for Prostate Cancer , 2003, BJU international.

[19]  R. Grobholz,et al.  Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients , 2004, Virchows Archiv.

[20]  Jason C. Massengill,et al.  Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. , 2003, The Journal of urology.

[21]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[22]  C. de la Piedra,et al.  Bone remodeling markers in the detection of bone metastases in prostate cancer. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[23]  C. Stephan,et al.  The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. , 2003, Cancer research.

[24]  F. Hamdy,et al.  Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer , 2004, The Prostate.

[25]  D Gillatt,et al.  Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. , 2003, Health technology assessment.

[26]  A. Uitterlinden,et al.  CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. , 2000, Clinical chemistry.

[27]  F. Hamdy,et al.  Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. , 1998, British Journal of Cancer.

[28]  Anssi Auvinen,et al.  Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening , 2004, International journal of cancer.

[29]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[30]  R. V. van Schaik,et al.  CYP3A5 variant allele frequencies in Dutch Caucasians. , 2002, Clinical chemistry.

[31]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[32]  K. Tsao,et al.  Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[33]  T. Wheeler,et al.  Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  B. G. Blijenberg,et al.  The value of (−7, −5)pro‐prostate‐specific antigen and human kallikrein‐2 as serum markers for grading prostate cancer , 2004, BJU international.

[35]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[37]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[38]  S. Cross,et al.  Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. , 2004, Urology.

[39]  H. Klocker,et al.  Ability of PSA‐positive circulating macrophages to detect prostate cancer , 2005, The Prostate.

[40]  M. Poupon,et al.  Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. , 2001, The Journal of urology.

[41]  U. Stenman,et al.  Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA. , 2003, Clinical chemistry.

[42]  Hartwig Huland,et al.  Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. , 2003, The Journal of urology.

[43]  Jianfeng Xu,et al.  Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk , 2003, International journal of cancer.

[44]  E. Bleecker,et al.  Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer , 2003, British Journal of Cancer.

[45]  E. Kikuchi,et al.  Prostate specific antigen adjusted for transition zone volume , 2000, Cancer.

[46]  B. Conley,et al.  Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.

[47]  M. Noguchi,et al.  Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. , 2001, The Journal of urology.

[48]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[49]  A. Partin,et al.  Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. , 1996, Human pathology.

[50]  M. Yashi,et al.  Elevated serum progastrin‐releasing peptide (31–98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer , 2003, The Prostate.

[51]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[52]  T. Habuchi,et al.  Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer , 2004, International journal of cancer.

[53]  Masatoshi Watanabe,et al.  CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. , 2005, European urology.

[54]  D. Albanes,et al.  Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. , 2003, Cancer research.

[55]  S. Loening,et al.  Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. , 2003, The Journal of urology.

[56]  U. Stenman,et al.  Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. , 2000, Urology.

[57]  H. Klocker,et al.  Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. , 2004, Clinical prostate cancer.

[58]  A. Haese*,et al.  Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. , 2002, The Journal of urology.